Total Funding
7
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
SynapDX is an early-stage laboratory services company developing blood-based diagnostic tests for the early detection of autism.
Bobbi Rathmell: Vice President and Medical DirectorPast Role: Seaside Therapeutics, worked
About the Company
SynapDx's mission is to provide laboratory testing services to physicians who evaluate children for developmental disorders with the initial goal of enabling earlier detection of autism.
Autism Spectrum Disorders are currently estimated to affect 1 in 110 children in the United States according to the Centers for Disease Control.
SynapDx
was founded by Stanley Lapidus and closed a Series A round of venture funding in May 2010 from North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.
SynapDx's corporate headquarters is located in Lexington, Massachusetts.
